14 results on '"Benzonana N"'
Search Results
2. Undiagnosed systemic lupus erythematosus presenting with salmonella bacteremia: a case report and mini-review
- Author
-
Gençer, S., Balkan, Ý. Ýnanç, Benzonana, N., and Özer, S.
- Published
- 2003
3. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- Author
-
Tacconelli, Evelina, Carrara, E., Savoldi, Alessandra, Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., Theuretzbacher, U., Magrini, N., Aboderin, A. O., Al-Abri, S. S., Awang Jalil, N., Benzonana, N., Bhattacharya, S., Brink, A. J., Burkert, F. R., Cars, O., Cornaglia, G., Dyar, O. J., Friedrich, A. W., Gales, A. C., Gandra, S., Giske, C. G., Goff, D. A., Goossens, H., Gottlieb, T., Guzman Blanco, M., Hryniewicz, W., Kattula, D., Jinks, T., Kanj, S. S., Kerr, L., Kieny, M. -P., Kim, Y. S., Kozlov, R. S., Labarca, J., Laxminarayan, R., Leder, K., Leibovici, L., Levy-Hara, G., Littman, J., Malhotra-Kumar, S., Manchanda, V., Moja, L., Ndoye, B., Pan, A., Paterson, D. L., Paul, M., Qiu, H., Ramon-Pardo, P., Rodriguez-Bano, J., Sanguinetti, Maurizio, Sengupta, S., Sharland, M., Si-Mehand, M., Silver, L. L., Song, W., Steinbakk, M., Thomsen, J., Thwaites, G. E., van der Meer, J. W., Van Kinh, N., Vega, S., Villegas, M. V., Wechsler-Fordos, A., Wertheim, H. F. L., Wesangula, E., Woodford, N., Yilmaz, F. O., Zorzet, A., Tacconelli E. (ORCID:0000-0001-8722-5824), Savoldi A., Sanguinetti M. (ORCID:0000-0002-9780-7059), Tacconelli, Evelina, Carrara, E., Savoldi, Alessandra, Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., Theuretzbacher, U., Magrini, N., Aboderin, A. O., Al-Abri, S. S., Awang Jalil, N., Benzonana, N., Bhattacharya, S., Brink, A. J., Burkert, F. R., Cars, O., Cornaglia, G., Dyar, O. J., Friedrich, A. W., Gales, A. C., Gandra, S., Giske, C. G., Goff, D. A., Goossens, H., Gottlieb, T., Guzman Blanco, M., Hryniewicz, W., Kattula, D., Jinks, T., Kanj, S. S., Kerr, L., Kieny, M. -P., Kim, Y. S., Kozlov, R. S., Labarca, J., Laxminarayan, R., Leder, K., Leibovici, L., Levy-Hara, G., Littman, J., Malhotra-Kumar, S., Manchanda, V., Moja, L., Ndoye, B., Pan, A., Paterson, D. L., Paul, M., Qiu, H., Ramon-Pardo, P., Rodriguez-Bano, J., Sanguinetti, Maurizio, Sengupta, S., Sharland, M., Si-Mehand, M., Silver, L. L., Song, W., Steinbakk, M., Thomsen, J., Thwaites, G. E., van der Meer, J. W., Van Kinh, N., Vega, S., Villegas, M. V., Wechsler-Fordos, A., Wertheim, H. F. L., Wesangula, E., Woodford, N., Yilmaz, F. O., Zorzet, A., Tacconelli E. (ORCID:0000-0001-8722-5824), Savoldi A., and Sanguinetti M. (ORCID:0000-0002-9780-7059)
- Abstract
Background: The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs. Methods: We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated. The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria. Findings: We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline. We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff. Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae. The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus. Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori, and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae, and Salmonella typhi were included in the high-priority tier. Interpretation: Fu
- Published
- 2018
4. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012
- Author
-
Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Midilli, K.; Erkılıç, A.; Kuskucu, M.; Analay, H.; Erkılıç, S.; Benzonana, N.; Yıldırım, M. S.; Muelayim, K.; Acar, H., School of Medicine, Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Midilli, K.; Erkılıç, A.; Kuskucu, M.; Analay, H.; Erkılıç, S.; Benzonana, N.; Yıldırım, M. S.; Muelayim, K.; Acar, H., and School of Medicine
- Abstract
We report the first outbreak of nosocomial orf infection in a hospital burn unit in Gaziantep, Turkey. The outbreak lasted from October to December 2012 and involved a total of thirteen cases. It demonstrates the risk of introduction of orf virus to a burn unit, and the potential for extensive transmission among patients with compromised skin integrity. The importance of hygiene measures and infection control are highlighted and possible transmission routes of the virus discussed., NA
- Published
- 2013
5. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012
- Author
-
Midilli, K, primary, Erkılıç, A, additional, Kuşkucu, M, additional, Analay, H, additional, Erkılıç, S, additional, Benzonana, N, additional, Yıldırım, M S, additional, Mülayim, K, additional, Acar, H, additional, and Ergonul, O, additional
- Published
- 2013
- Full Text
- View/download PDF
6. Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey
- Author
-
Özer Serdar, Batırel Ayşe, Benzonana Nur, Ak Öznur, and Gençer Serap
- Subjects
Therapeutics. Pharmacology ,RM1-950 ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
Abstract Background Pseudomonas aeruginosa is the third most common pathogen responsible for nosocomial infections and the prevalence of multiple resistant isolates has been increasing. Ninety-nine clinical isolates were studied in order to assess the current levels of susceptibility and cross-resistances of widely used antipseudomonal antibiotics against P. aeruginosa and to determine some resistance mechanisms by phenotypic methods. Methods MICs of isolates for nine antipseudomonal antibiotics were determined by the E test method. Results Thirty-six percent of isolates were resistant to more than one group of antibiotics. The rates of susceptible isolates were ciprofloxacin 75%, amikacin 73%, ceftazidime 65%, meropenem 63%, imipenem 63%, piperacillin/tazobactam 60%, cefoperazone/sulbactam 59%, cefepime 54% and tobramycin 44%. The majority of carbapenem resistant isolates were susceptible to ciprofloxacin and amikacin. Conclusion Ciprofloxacin seems to be the most active agent against P. aeruginosa followed by amikacin in our unit. The usefulness of combinations of these antibiotics and β-lactams should be tested in treating multi-drug resistant P. aeruginosa.
- Published
- 2002
- Full Text
- View/download PDF
7. Hyperbaric oxygen treatment for toxic epidermal necrolysis: A case report.
- Author
-
Gamze Sümen S, Yakupoğlu S, Gümüş T, and Benzonana N
- Subjects
- Critical Care, Female, Humans, Middle Aged, Oxygen, Hyperbaric Oxygenation, Stevens-Johnson Syndrome therapy
- Abstract
Toxic epidermal necrolysis (TEN) is a potentially life-threatening muco-cutaneous disease, largely caused by an idiosyncratic reaction to medication or infectious disease, and is characterised by acute necrosis of the epidermis. No definitive consensus regarding the treatment of TEN has been agreed. A 60-year-old woman, diagnosed with multiple myeloma three months prior, was admitted with signs of TEN to the intensive care burns unit. She had been given ciprofloxacin to treat a urinary tract infection. She complained of malaise and pain, with maculopapular and bullous eruptions over her whole body on the third day of ciprofloxacin administration. Her supportive cares included intravenous immunoglobulins, pain control with analgesics, wound care, nutrition, and fluid support. Hyperbaric oxygen treatment (HBOT) was added on the second day of admission. The patient underwent 5 sessions of HBOT at 243.1 kPa (2.4 atmospheres absolute). Desquamation was noted to stop after the first session of HBOT and re-epithelisation commenced rapidly. The patient was discharged from the burn unit after 14 days of hospital admission. Improvement in this case was temporally related to the initiation of HBOT., (Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.)
- Published
- 2021
- Full Text
- View/download PDF
8. Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infection.
- Author
-
Can F, Menekse S, Ispir P, Atac N, Albayrak O, Demir T, Karaaslan DC, Karahan SN, Kapmaz M, Kurt Azap O, Timurkaynak F, Simsek Yavuz S, Basaran S, Yoruk F, Azap A, Koculu S, Benzonana N, Lack NA, Gönen M, and Ergonul O
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Gene Expression Profiling, Hospitals, Humans, Infant, Infant, Newborn, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae genetics, Klebsiella pneumoniae isolation & purification, Male, Middle Aged, Multilocus Sequence Typing, Polymerase Chain Reaction, Prospective Studies, Sequence Analysis, DNA, Survival Analysis, Turkey epidemiology, Young Adult, Anti-Bacterial Agents pharmacology, Colistin pharmacology, Drug Resistance, Bacterial, Genotype, Klebsiella Infections microbiology, Klebsiella Infections mortality, Klebsiella pneumoniae classification
- Abstract
Objectives: We describe the molecular characteristics of colistin resistance and its impact on patient mortality., Methods: A prospective cohort study was performed in seven different Turkish hospitals. The genotype of each isolate was determined by MLST and repetitive extragenic palindromic PCR (rep-PCR). Alterations in mgrB were detected by sequencing. Upregulation of pmrCAB, phoQ and pmrK was quantified by RT-PCR. mcr-1 and the genes encoding OXA-48, NDM-1 and KPC were amplified by PCR., Results: A total of 115 patients diagnosed with colistin-resistant K. pneumoniae (ColR-Kp) infection were included. Patients were predominantly males (55%) with a median age of 63 (IQR 46-74) and the 30 day mortality rate was 61%. ST101 was the most common ST and accounted for 68 (59%) of the ColR-Kp. The 30 day mortality rate in patients with these isolates was 72%. In ST101, 94% (64/68) of the isolates had an altered mgrB gene, whereas the alteration occurred in 40% (19/47) of non-ST101 isolates. The OXA-48 and NDM-1 carbapenemases were found in 93 (81%) and 22 (19%) of the total 115 isolates, respectively. In multivariate analysis for the prediction of 30 day mortality, ST101 (OR 3.4, CI 1.46-8.15, P = 0.005) and ICU stay (OR 7.4, CI 2.23-29.61, P = 0.002) were found to be significantly associated covariates., Conclusions: Besides ICU stay, ST101 was found to be a significant independent predictor of patient mortality among those infected with ColR-Kp. A significant association was detected between ST101 and OXA-48. ST101 may become a global threat in the dissemination of colistin resistance and the increased morbidity and mortality of K. pneumoniae infection.
- Published
- 2018
- Full Text
- View/download PDF
9. Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults.
- Author
-
Ergönül Ö, Alan S, Ak Ö, Sargın F, Kantürk A, Gündüz A, Engin D, Öncül O, Balkan II, Ceylan B, Benzonana N, Yazıcı S, Şimşek F, Uzun N, Inan A, Gulhan E, Ciblak M, Midilli K, Ozyurt M, Badur S, Gencer S, Nazlıcan O, Özer S, Özgüneş N, Yıldırmak T, Aslan T, Göktaş P, Saltoğlu N, Fincancı M, Dokucu AI, and Eraksoy H
- Subjects
- Adult, Antiviral Agents therapeutic use, Cross Infection epidemiology, Cross Infection mortality, Disease Outbreaks, Female, Hospitalization, Humans, Influenza A Virus, H1N1 Subtype pathogenicity, Influenza, Human drug therapy, Influenza, Human epidemiology, Influenza, Human virology, Male, Middle Aged, Multivariate Analysis, Neuraminidase antagonists & inhibitors, Odds Ratio, Oseltamivir therapeutic use, Pregnancy, Turkey epidemiology, Zanamivir therapeutic use, Influenza, Human mortality
- Abstract
Background: The fatality attributed to pandemic influenza A H1N1 was not clear in the literature. We described the predictors for fatality related to pandemic influenza A H1N1 infection among hospitalized adult patients., Methods: This is a multicenter study performed during the pandemic influenza A H1N1 [A(H1N1)pdm09] outbreak which occurred in 2009 and 2010. Analysis was performed among laboratory confirmed patients. Multivariate analysis was performed for the predictors of fatality., Results: In the second wave of the pandemic, 848 adult patients were hospitalized because of suspected influenza, 45 out of 848 (5.3%) died, with 75% of fatalities occurring within the first 2 weeks of hospitalization. Among the 241 laboratory confirmed A(H1N1)pdm09 patients, the case fatality rate was 9%. In a multivariate logistic regression model that was performed for the fatalities within 14 days after admission, early use of neuraminidase inhibitors was found to be protective (Odds ratio: 0.17, confidence interval: 0.03-0.77, p=0.022), nosocomial infections (OR: 5.7, CI: 1.84-18, p=0.013), presence of malignant disease (OR: 3.8, CI: 0.66-22.01, p=0.133) significantly increased the likelihood of fatality., Conclusions: Early detection of the infection, allowing opportunity for the early use of neuraminidase inhibitors, was found to be important for prevention of fatality. Nosocomial bacterial infections and underlying malignant diseases increased the rate of fatality.
- Published
- 2014
- Full Text
- View/download PDF
10. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis.
- Author
-
Cakır Madenci Ö, Yakupoğlu S, Benzonana N, Yücel N, Akbaba D, and Orçun Kaptanağası A
- Subjects
- Adult, Burns complications, Calcitonin Gene-Related Peptide, Cohort Studies, Female, Humans, Leukocyte Count, Male, Middle Aged, Prospective Studies, ROC Curve, Sepsis blood, Sepsis etiology, Young Adult, Burns blood, C-Reactive Protein metabolism, Calcitonin blood, Lipopolysaccharide Receptors blood, Peptide Fragments blood, Protein Precursors blood, Sepsis diagnosis
- Abstract
Background: Diagnosing sepsis is difficult in burn patients because of the inflammatory mediators that alter postburn metabolic profile. Here, we compare a new marker presepsin with procalcitonin (PCT), c-reactive protein (CRP) and white blood cell (WBC) in diagnosis and follow up of sepsis in burn patients., Methods: Patients admitted to burn center of our institute were prospectively investigated. Presepsin, PCT, CRP and WBC levels were measured at admission and every 6h for first day and daily thereafter. At all timing samples, patients were classified as sepsis or non-sepsis according to the current American Burn Association Consensus Criteria (ABA) 2007., Result: 37 adult patients were evaluated. A total data of 611 time points were supplied. Sepsis time points differ significantly from non-sepsis in presepsin (p < 0.0001), PCT (p = 0.0012) and CRP (p < 0.0001) levels. Non-surviving patient results differ significantly from survivors in presepsin (p < 0.0001), PCT (p = 0.0210) and CRP (p = 0.0008). AUC-ROC % values for diagnosing sepsis were 83.4% for presepsin, 84.7% for PCT, 81.9% for CRP and 50.8% for WBC. Sepsis patients had significantly different presepsin, CRP and WBC but not PCT levels on their first day of sepsis compared to previous days., Conclusion: Plasma presepsin levels have comparable performance in burn sepsis., (Copyright © 2013 Elsevier Ltd and ISBI. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
11. Influenza B-associated encephalopathy in two adults.
- Author
-
Ak Ö, Biteker F, Cag Y, Öcal G, Benzonana N, Ciblak MA, and Özer S
- Subjects
- Brain pathology, Brain physiopathology, Electroencephalography, Encephalitis, Viral cerebrospinal fluid, Female, Humans, Influenza, Human cerebrospinal fluid, Magnetic Resonance Imaging, Male, Middle Aged, Encephalitis, Viral virology, Influenza B virus isolation & purification, Influenza, Human virology
- Abstract
Influenza virus is associated with a variety of neurological complications, of which the most commonly encountered are seizures and encephalopathy. Acute encephalitis and postinfectious encephalopathy have been reported infrequently in association with influenza A and B virus infections. We describe two previously healthy adults who presented with encephalopathy with a virologically documented influenza B infection.
- Published
- 2012
- Full Text
- View/download PDF
12. Science without meritocracy. Discrimination among European specialists in infectious diseases and clinical microbiology: a questionnaire survey.
- Author
-
Tacconelli E, Poljak M, Cacace M, Caiati G, Benzonana N, Nagy E, and Kortbeek T
- Abstract
Objective: In 2009, in a European survey, around a quarter of Europeans reported witnessing discrimination or harassment at their workplace. The parity committee from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) designed a questionnaire survey to investigate forms of discrimination with respect to country, gender and ethnicity among medical professionals in hospitals and universities carrying out activities in the clinical microbiology (CM) and infectious diseases (ID) fields., Design: The survey consisted of 61 questions divided into five areas (sociodemographic, professional census and environment, leadership and generic) and ran anonymously for nearly 3 months on the ESCMID website., Subjects: European specialists in CM/ID., Results: Overall, we included 1274 professionals. The majority of respondents (68%) stated that discrimination is present in medical science. A quarter of them reported personal experience with discrimination, mainly associated with gender and geographic region. Specialists from South-Western Europe experienced events at a much higher rate (37%) than other European regions. The proportion of women among full professor was on average 46% in CM and 26% in ID. Participation in high-level decision-making committees was significantly (>10 percentage points) different by gender and geographic origin. Yearly gross salary among CM/ID professionals was significantly different among European countries and by gender, within the same country. More than one-third of respondents (38%) stated that international societies in CM/ID have an imbalance as for committee member distribution and speakers at international conferences., Conclusions: A quarter of CM/ID specialists experienced career and research discrimination in European hospitals and universities, mainly related to gender and geographic origin. Implementing proactive policies to tackle discrimination and improve representativeness and balance in career among CM/ID professionals in Europe is urgently needed.
- Published
- 2012
- Full Text
- View/download PDF
13. Pseudallescheria boydii keratitis.
- Author
-
Ozkurt Y, Oral Y, Kulekci Z, Benzonana N, Ustaoglu R, and Dogan OK
- Subjects
- Adolescent, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Cyclopentolate therapeutic use, Drug Therapy, Combination, Eye Infections, Fungal diagnosis, Eye Infections, Fungal drug therapy, Glucocorticoids therapeutic use, Humans, Keratitis diagnosis, Keratitis drug therapy, Male, Mycetoma diagnosis, Mycetoma drug therapy, Natamycin therapeutic use, Prednisolone analogs & derivatives, Prednisolone therapeutic use, Eye Infections, Fungal microbiology, Keratitis microbiology, Mycetoma microbiology, Pseudallescheria isolation & purification
- Abstract
We describe a patient with Pseudallescheria boydii keratitis. The treatment of mycotic keratitis remains difficult. This case demonstrates that identification and susceptibility testing should be rapidly performed. In cases of indolent keratitis, the possibility of fungal infection should be kept in mind.
- Published
- 2006
- Full Text
- View/download PDF
14. Emergence of high-level fluoroquinolone-resistant Streptococcus pneumoniae in Turkey.
- Author
-
Ak O O, Benzonana N, Ozer S, and Eraksoy H
- Subjects
- Drug Resistance, Bacterial, Humans, Immunocompromised Host, Male, Microbial Sensitivity Tests, Middle Aged, Pneumococcal Infections microbiology, Streptococcus pneumoniae isolation & purification, Turkey, Anti-Bacterial Agents pharmacology, Fluoroquinolones pharmacology, Pneumococcal Infections drug therapy, Streptococcus pneumoniae drug effects
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.